Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
HUTCHMED HK$4.17 billion IPO and primary listing
The shares are listed on the Hong Kong Stock Exchange
GH Research $184 million IPO
We advised GH Research on the IPO and Nasdaq Listing
Theravance Biopharma $100.5 million follow-on offering
We advised the underwriters on the equity offering
ATAI Life Sciences $258.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Century Therapeutics $242.7 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Cyteir Therapeutics $133.2 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Convey Holding Parent $186.7 million IPO
We advised the underwriters on the IPO and NYSE listing
Molecular Partners $64 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
RAPT Therapeutics $143.7 million follow-on offering
We advised the joint book-running managers on the SEC-registered equity offering
CARsgen Therapeutics HK$3.1 billion IPO
We advised CARsgen Therapeutics on its IPO and HKEX listing